Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease

Fassett, Robert G., Robertson, Iain K., Ball, Madeleine J., Geraghty, Dominic P. and Coombes, Jeff S. (2014) Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease. Clinical Nephrology, 81 2: 75-85. doi:10.5414/CN108090

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Fassett, Robert G.
Robertson, Iain K.
Ball, Madeleine J.
Geraghty, Dominic P.
Coombes, Jeff S.
Title Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease
Journal name Clinical Nephrology   Check publisher's open access policy
ISSN 0301-0430
Publication date 2014-02-01
Year available 2014
Sub-type Article (original research)
DOI 10.5414/CN108090
Volume 81
Issue 2
Start page 75
End page 85
Total pages 11
Place of publication Oberhaching, Germany
Publisher Dustri-Verlag Dr. Karl Feistle
Language eng
Formatted abstract
Background: Chronic kidney disease (CKD) is associated with inflammation. The effects of atorvastatin on biomarkers of inflammation were assessed in CKD patients in the LORD trial.

117 patients with serum creatinine > 120 μmol/L were randomized to receive atorvastatin 10 mg/day (56) or placebo (61) and followed for a mean of 2.5 years. 33 individuals with normal kidney function were controls. Outcomes included comparison of changes in pentraxin-3 (PTX3), TNF-α, CRP, IL-6, IL-8, and IL-10 between atorvastatin and placebo-treated patients.

Results: At baseline, compared with controls, CKD patients had increased PTX3 (mean, 1.08 vs. 0.58 ng/mL; p < 0.001), CRP (4.9 vs. 1.5 mg/L; p < 0.001), IL-8 (6.00 vs. 4.58 pg/mL; p = 0.001), IL-10 (59.0 vs. 17.6 pg/mL; p = 0.007), and TNF-a (18.0 vs. 5.6 ng/mL; p < 0.001). In patients with raised baseline plasma IL-6/8/10 and/or PTX3 the eGFR decline during the trial was significantly less in those treated with atorvastatin compared to placebo (mean change, -3.36; vs. + 1.25 mL/min/1.73 m2/year; difference, 4.61 95% CI 0.98 - 8.25; p = 0.002), whilst those without raised inflammatory biomarkers showed no difference. Placebotreated patients with raised TNF-α levels had no eGFR decline (p > 0.90), whereas in atorvastatin-treated patients eGFR declined (p = 0.05).

Conclusions: CKD patients with inflammation treated with atorvastatin had significantly less eGFR decline. Larger studies using statin therapy, specifically enrolling CKD patients with inflammation, may be worthwhile exploring.
Keyword CRP
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2015 Collection
School of Human Movement and Nutrition Sciences Publications
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 10 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 10 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 18 Feb 2014, 10:26:15 EST by System User on behalf of School of Human Movement and Nutrition Sciences